Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vaccine Preclinical Toxicity Study Guidance Under Development

Executive Summary

FDA's Center for Biologics Evaluation & Research is producing a guidance for industry on preclinical toxicity studies for vaccines

You may also be interested in...



Vaccine Preclinical Toxicity Study Workshop Will Address Dosing And Design

A workshop by FDA's Center for Biologics Evaluation & Research on preventative vaccine development Dec. 2-3 will consider the maximum dose for animal toxicology studies

Vaccine Preclinical Toxicity Study Workshop Will Address Dosing And Design

A workshop by FDA's Center for Biologics Evaluation & Research on preventative vaccine development Dec. 2-3 will consider the maximum dose for animal toxicology studies

FDA Pediatrics Office Under Murphy Plans To Recruit Review Div. Liaisons

FDA's Office of Pediatric Drug Development & Special Initiatives hopes to attract an expert from every drug review division to serve as a liaison in assessing pediatric drug applications.

Related Content

UsernamePublicRestriction

Register

PS039759

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel